Share on StockTwits

Sagent Pharmaceuticals (NASDAQ:SGNT) Director Robert J. Flanagan unloaded 16,000 shares of Sagent Pharmaceuticals stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $22.17, for a total value of $354,720.00. Following the completion of the sale, the director now directly owns 6,996 shares in the company, valued at approximately $155,101. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Sagent Pharmaceuticals (NASDAQ:SGNT) traded down 0.05% during mid-day trading on Wednesday, hitting $22.18. 125,647 shares of the company’s stock traded hands. Sagent Pharmaceuticals has a one year low of $17.49 and a one year high of $26.08. The stock’s 50-day moving average is $21.31 and its 200-day moving average is $22.1. The company has a market cap of $706.8 million and a P/E ratio of 27.33.

Sagent Pharmaceuticals (NASDAQ:SGNT) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.18. The company had revenue of $70.90 million for the quarter, compared to the consensus estimate of $65.66 million. The company’s revenue for the quarter was up 17.8% on a year-over-year basis. Analysts expect that Sagent Pharmaceuticals will post $0.14 EPS for the current fiscal year.

A number of analysts have recently weighed in on SGNT shares. Analysts at Jefferies Group reiterated a “hold” rating on shares of Sagent Pharmaceuticals in a research note on Thursday, May 15th. They now have a $23.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated a “hold” rating on shares of Sagent Pharmaceuticals in a research note on Wednesday, May 7th. They now have a $24.00 price target on the stock, up previously from $22.00. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $23.62.

Sagent Pharmaceuticals, Inc (NASDAQ:SGNT) is an injectable pharmaceutical company, which develops and sources products, which the Company sells in the United States.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.